Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
HOUSTON, May 1, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the formation of its Annamycin Scientific Advisory Board and inaugural appointment of Dr. Martin Tallman.
- Walter Klemp, Chairman and Chief Executive Officer of Moleculin commented, "We continue to be encouraged by the growing body of data Annamycin has demonstrated across our ongoing development programs.
- As we continue on our pathway forward, we are pleased to bolster our Annamycin development programs with the formation of this Scientific Advisory Board and add the internationally-renowned knowledge and expertise of Dr. Tallman.
- We are committed to advancing our clinical and regulatory strategies toward our next phase of development for Annamycin."
- Dr. Tallman added, "The latest preliminary AML data suggest that Annamycin could result in a promising new the treatment for AML.